SL9, HIV - 1 p17 (77 - 85)

HIV-1 gag p17 protein is an attractive target for molecular intervention, because it is involved in the viral replication cycle at both the pre- and postintegration levels. P17gag targets the viral RNA to the nucleus of the cell and targets the GAG polyproteins to the cellular membrane.

SL9, HIV - 1 p17 (77 - 85) is a synthetic HIV-derived research peptide. Synthetic peptides derived from HIV proteins have long been used to map B-cell and T-cell determinants, define HLA-restricted cytotoxic T-lymphocyte epitopes, study viral protein interactions, and provide sequence-defined controls for immunological assays. Because HIV proteins are highly variable and peptide function depends strongly on the source protein, residue range, viral subtype, and HLA allele, biological interpretation should be made for the exact product sequence rather than for HIV-derived peptides as a single class.

• HIV-specific T-cell assays
• HLA-restricted epitope mapping
• antibody-binding studies
• viral protein interaction experiments
• sequence-variant and subtype comparisons

For antigenic or viral peptides, HLA restriction, cellular response, and immunological activity should not be inferred solely from the source protein name; the exact sequence, residue numbering, strain or genotype, and experimental system should be considered. For labeled or otherwise modified variants, the modification may also affect binding or assay behavior.

1. T cell recognition of HIV synthetic peptides in natural infection
2. Helper and cytotoxic T cell responses of HIV-1-infected individuals to synthetic peptides